189,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
payback
95 °P sammeln
  • Gebundenes Buch

Managing patients with thrombotic vascular disease is complex and challenging: Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis--even with the evolution in our understanding of the pathobiology of thrombosis. There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents
Now more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other
…mehr

Produktbeschreibung
Managing patients with thrombotic vascular disease is complex and challenging:
Ischemic vascular disease remains a complicated interplay of atherosclerosis and thrombosis--even with the evolution in our understanding of the pathobiology of thrombosis.
There has been tremendous growth in therapeutic options which are quickly finding their place in daily practice, including a remarkable expansion in the number of intravenous and oral antithrombotic agents and new antiplatelet agents

Now more than ever, all cardiologists, hematologists, and specialists in vascular medicine, as well as other professionals, such as hospital pharmacists, who deal with prognosis and intervention in preventing thrombosis, need a resource that distills current knowledge of this important subject.

Written and edited by today's leading international, Therapeutic Advances in Thrombosis, 2e provides physicians with the very latest in medical and surgical advances in antithrombotic therapies. With this comprehensively updated edition you get:
Coverage of virtually all aspects of venous and arterial thrombotic disease and the corresponding therapies
Strategies to manage specific clinical conditions and how to tailor treatment to individual patient needs
Updated chapters covering thrombolysis in ST-elevated myocardial infarctions; thrombosis in patients with diabetes, pregnancy, and renal dysfunction
Special emphasis on the pharmacology of novel anticoagulants and their practical use in venous thromboembolism and atrial fibrillation.

Plus, all chapters fully explore clinical trial designs and outcomes for particular treatment therapies, as well as contain the relevant ACC/AHA/ESC guidelines, so you can confidently apply what you learn.
Autorenporträt
David Moliterno, M.D, co-director of the Gill Heart Institute, professor of Internal Medicine and division chief of Cardiovascular Medicine at the University of Lexington, Kentucky. He is also inaugurated as the American College of Cardiology Governor of the Kentucky chapter for the years 2007-2010. He has 189 articles published as listed on PubMed and is the author of the following books: Therapeutic Strategies in Thrombosis 1E; 900 Questions: An Interventional Cardiology Board Review. Raffaele De Caterina, MD, Institute of Cardiology, "G. d'Annunzio" University, Chieti, Italy. He has 261 articles published as listed on PubMed and is the author of the following books: Therapeutic Strategies in Thrombosis 1E; Endothelial Dysfunctions and Vascular Disease. Steen Dalby Kristensen, Department of Cardiology, Aarhus University Hospital, Aarhus N, Denmark. He has 91 articles published as listed on PubMed and is the author of the following books: Therapeutic Strategies in Thrombosis 1E.